Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Anetumab ravtansine + Itraconazole |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Anetumab ravtansine | BAY94-9343|BAY 94-9343 | MSLN Antibody 13 | Anetumab ravtansine (BAY94-9343) is a monoclonal antibody against mesothelin (MSLN) in conjugation with maytansinoid DM4, which delivers maytansinoid DM4 to tumor cells over expressing mesothelin, resulting in tumor cell death (PMID: 24714131, PMID: 32815024, PMID: 32213105). | |
| Itraconazole | Hyphanox | ITC | mTOR Inhibitor 51 | Itraconazole is an antifungal, which indirectly targets mTOR (PMID: 20176935). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |